• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br References br Boorjian SA Thompson RH Tollefson


    [2] Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893–9.
    [3] Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophili-city and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688–97.
    [5] Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197–209.
    [7] Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:926–37.
    [8] Rauscher I, Duewel C, Haller B, et al. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific mem-brane antigen-ligand positron-emission tomography/computed to-mography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol 2018;73:656–61. [9] Guideline EAU. Prostate cancer: guidelines for imaging in patients with biochemical recurrence. 2017 prostate-cancer/?type=summary-of-changes
    [11] Robu S, Schottelius M, Eiber M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med 2017;58:235–42. [12] Maurer T, Weirich G, Schottelius M, et al. Prostate-specific mem-brane antigen-radioguided surgery for metastatic Z-Guggulsterone nodes in prostate cancer. Eur Urol 2015;68:530–4. [13] Rauscher I, Duwel C, Wirtz M, et al. Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 2017;120:40–7. [14] Benz P, Oberhausen E, Berberich R. Monoclonal antibody BW431/26 labelled with technetium 99m and indium 111: an investigation of the biodistribution and the dosimetry in patients. Eur J Nucl Med 1991;18:813–6. 
    [15] Bunschoten A, van den Berg NS, Valdés Olmos RA, Blokland JAK, van Leeuwen FWB. Tracers applied in radioguided surgery. In: Hermann K, Nieweg OE, Povosiki SP, editors. Radioguided surgery—current applications and innovation directions in clinical practice.. Heidel-berg, Germany: Springer International Publishing; 2016.
    [16] Genders TS, Spronk S, Stijnen T, Steyerberg EW, Lesaffre E, Hunink MG. Methods for calculating sensitivity and specificity of clustered data: a tutorial. Radiology 2012;265:910–6. [17] Jilg CA, Drendel V, Rischke HC, et al. Diagnostic accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before salvage lymph node dissec-tion for recurrent prostate cancer. Theranostics 2017;7:1770–80. [18] Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum fol-low-up of 5 years. Eur Urol 2015;67:299–309.
    [19] Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathol-ogy after salvage lymphadenectomy. J Nucl Med 2016;57:1713–9.
    [23] van Oosterom MN, Simon H, Mengus L, et al. Revolutionizing (robot-assisted) laparoscopic gamma tracing using a drop-in gam-ma probe technology. Am J Nucl Med Mol Imaging 2016;6:1–17.
    [24] Baranski AC, Schafer M, Bauder-Wust U, et al. PSMA-11 derived dual-labeled PSMA-inhibitors for preoperative PET imaging and precise fluorescence-guided surgery of prostate cancer. J Nucl Med. In press. doi:10.2967/jnumed.117.201293.